Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02486718 · ClinicalTrials.gov registry record · Phase 3
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 3
- Development phase
- 1,280
- Enrollment target
- 20
- Study locations
NCT02486718 is a Phase 3 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 1,280 participants, above the 656-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (95% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT02486718, a Phase 3 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,280 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with Stage IB-Stage IIIA non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy, as measured by disease-free survival (DFS) as assessed by the investigator and overall survival (OS). Participants, after completing up to 4 cycles of adjuvant cisplatin-based chemotherapy, will be randomized in a 1:1 ratio to receive atezolizumab for 16 cycles or BSC.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Atezolizumab
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG Vinorelbine
Study Locations (20)
California
- California Cancer Associates for Research & Excellence, Inc. - Encinitas
- Compassionate Cancer Care Medical Group, Inc - Fountain Valley
- University of California Los Angeles - Los Angeles
- Kaiser Permanente - Vallejo
- Kaiser Permanente - Walnut Creek - Walnut Creek
New Jersey
- Hematology Oncology Associates of Northern New Jersey - Florham Park
- Saint Barnabas Medical Center - Livingston
- Valley Hospital - Paramus
- Overlook Medical Center - Summit
Florida
- Lynn Cancer Institute - West - Boca Raton
- University of Miami School of Medicine - Sylvester at Deerfield - Deerfield Beach
- SCRI Florida Cancer Specialists North - St. Petersburg
Illinois
- University of Illinois at Chicago - Chicago
- Illinois Cancer Care - Peoria
Arkansas
- Highlands Oncology Group - Fayetteville
Connecticut
- Eastern Connecticut Hematology and Oncology Associates - Norwich
Georgia
- Lewis Hall Singletary Oncology Center - Thomasville
Kentucky
- Norton Cancer Institute - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,280 participants |
| Start Date | 2015-10-31 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02486718
The ClinicalTrials.gov registry entry for NCT02486718 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,280 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 656-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (95% higher). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Docetaxel is the first listed.
NCT02486718 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, New Jersey, Florida.
Frequently Asked Questions
What is clinical trial NCT02486718 about?
NCT02486718 is a clinical study titled "Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]". This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with Stage IB-Stage IIIA non-small cell lung cancer (NSCLC)...
What is the current status of trial NCT02486718?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,280 participants. The study started on 2015-10-31. Estimated completion is 2027-08-31.
What conditions does trial NCT02486718 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT02486718?
The interventions under investigation include: Docetaxel (DRUG), Atezolizumab (DRUG), Cisplatin (DRUG), Gemcitabine (DRUG), Vinorelbine (DRUG).
Who is sponsoring clinical trial NCT02486718?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02486718 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.